Longevity Drugs for Dogs
Founded 2020 · 6 known investors
Loyal develops longevity drugs for dogs, targeting the biological processes of aging to extend healthy lifespan and reduce age-associated disease. Its lead drug candidate, LOY-002, is a once-daily pill for senior dogs that addresses metabolic dysfunction and is progressing through FDA conditional approval, alongside a broader portfolio of aging therapeutics and educational resources for veterinarians.
BiotechLongevity
Founders & leadership
Longevity Drugs for Dogs was founded in 2020 by Celine Halioua.
CH
Investors · 6
Frequently asked questions
- What does Longevity Drugs for Dogs do?
- Loyal develops longevity drugs for dogs, targeting the biological processes of aging to extend healthy lifespan and reduce age-associated disease. Its lead drug candidate, LOY-002, is a once-daily pill for senior dogs that addresses metabolic dysfunction and is progressing through FDA conditional approval, alongside a broader portfolio of aging therapeutics and educational resources for veterinarians.
- Who founded Longevity Drugs for Dogs?
- Longevity Drugs for Dogs was founded by Celine Halioua in 2020.
- Who are Longevity Drugs for Dogs's investors?
- Longevity Drugs for Dogs's investors include First Round Capital, Invariantes Fund, MVP Ventures, Predictive VC, Spacecadet Ventures, Todd and Rahul’s Angel Fund.